Dosage of heparin for patency of the totally implanted central venous catheter in cancer patients

OBJECTIVE: to analyze the evidence available in the literature about the lowest necessary dose of heparin to maintain the patency of the totally implanted central venous catheter in adult cancer patients. METHOD: an integrative literature review, carried out in the following databases: Literatura La...

Descripción completa

Detalles Bibliográficos
Autores principales: de Oliveira, Francisca Jane Gomes, Rodrigues, Andrea Bezerra, Ramos, Islane Costa, Caetano, Joselany Áfio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Escola de Enfermagem de Ribeirão Preto / Universidade de São Paulo 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304977/
https://www.ncbi.nlm.nih.gov/pubmed/32578754
http://dx.doi.org/10.1590/1518-8345.3326.3304
Descripción
Sumario:OBJECTIVE: to analyze the evidence available in the literature about the lowest necessary dose of heparin to maintain the patency of the totally implanted central venous catheter in adult cancer patients. METHOD: an integrative literature review, carried out in the following databases: Literatura Latino-Americana e do Caribe em Ciências de Saúde, Sciverse Scopus, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, including thirteen studies. RESULTS: the evidence showed that the dose of heparin (300 IU/ml) is the most used in maintaining the patency of the totally implanted central venous catheter. CONCLUSION: according to the selected studies, the lowest dose of heparin found in maintaining the patency of the totally implanted central venous catheter in cancer patients was 10 UN/ml with a volume of 5 ml of the heparin solution.

Ejemplares similares